The US services giant Salesforce (CRM.US) loses almost 6% today on disappointing guidance. Salesforce shares are hurt after the company issued weaker-than-expected revenue guidance.
-
The stock is now down almost 27% in 2025, making it the worst performer among large-cap tech companies this year. Despite the slump, Salesforce’s Q2 revenue rose 10% year-over-year to $10.24 billion, beating Wall Street expectations.
-
Earnings per share also topped estimates, showing operational strength. For Q3, Salesforce forecasted $10.24–$10.29 billion in revenue. It's slightly below analysts’ $10.29 billion projection.
-
Investors worry that artificial intelligence could erode traditional software demand, creating long-term uncertainty for SaaS providers. Salesforce says it’s investing heavily in AI, but hasn’t enjoyed the same market boost as peers focused on infrastructure.
-
The company closed 12,500 Agentforce deals, including 6,000 paid contracts, with 40% of bookings coming from existing clients. CEO Marc Benioff dismissed AI-related fears, calling them “nonsense” and highlighting an ongoing “great transformation” in software.
-
Salesforce kept its full-year revenue outlook, which may be a signal that company organic growth is slowing, but raised its earnings guidance, now targeting $11.33–$11.37 adjusted EPS on $41.1–$41.3 billion revenue.
Salesforce shares (D1 interval)
Source: xStation5
Salesforce announces partnerships with OpenAI and Anthropic🚨
Intel down 5% 📉
JPMorgan, Goldman Sachs, and Citigroup: Sector Overview and Challenges
AMD Gains 3% on Oracle Processor Integration Announcement
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
